First intention IVF protocol for polycystic ovaries: Does oral contraceptive pill pretreatment influence COH outcome?

Reproductive Biology and Endocrinology

Volumn 11, Issue 1, 2013, Pages

  Decanter, Christine ^a   Robin, Geoffroy ^a   Thomas, Patricia ^a   Leroy, Maryse ^a   Lefebvre, Catherine ^a   Soudan, Benoit ^a   Lefebvre Khalil, Valerie ^a   Leroy Martin, Brigitte ^a   Dewailly, Didier ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

COH outcome; Embryo; GnRH agonist; IVF; OCP; Oocyte; PCO; PCOS; Pretreatment; Rotterdam ultrasonographic criteria

Indexed keywords

ANDROGEN; DESOGESTREL; ETHINYLESTRADIOL; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; EMBRYO; ENDOMETRIAL THICKNESS; FEMALE; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY;

ADULT; ANDROSTENEDIONE; CONTRACEPTIVES, ORAL; DESOGESTREL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMBRYO TRANSFER; ETHINYL ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TESTOSTERONE; TREATMENT OUTCOME; TRIPTORELIN PAMOATE; YOUNG ADULT;

EID: 84879049233     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-11-54     Document Type: Article

References (25)

1. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81(1):19-25. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.
2. Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, Coulson C, Lambert PA, Watt EM, Desai KM. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985, 291(6510):1693-1697.
3. Kim YJ, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM, Kim JG, Moon SY. A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles. Arch Gynecol Obstet 2010, 282(2):199-205. 10.1007/s00404-010-1401-9, 20182736.
4. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010, 25(2):544-551. 10.1093/humrep/dep399, 19910321.
5. Mortensen M, Ehrmann DA, Littlejohn E, Rosenfield RL. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 2009, 94(5):1579-1586. 10.1210/jc.2008-2771, 2684482, 19240158.
6. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 2003, 9(3):275-289. 10.1093/humupd/dmg018, 12859048.
7. Delvigne A, Kostyla K, Murillo D, Van Hoeck J, Rozenberg S. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2003, 48(1):25-31.
8. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006, 12(1):13-21.
9. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008, 14(4):367-378. 10.1093/humupd/dmn015, 18499708.
10. Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod 2009, 24(7):1548-1555. 10.1093/humrep/dep049, 19279033.
11. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004, 10(2):107-117. 10.1093/humupd/dmh010, 15073141.
12. Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development. Semin Reprod Med 2008, 26(1):53-61. 10.1055/s-2007-992925, 2655636, 18181083.
13. Damario MA, Moomjy M, Tortoriello D, Moy F, Davis OK, Rosenwaks Z. Delay of gonadotropin stimulation in patients receiving gonadotropin-releasing hormone agonist (GnRH-a) therapy permits increased clinic efficiency and may enhance in vitro fertilization (IVF) pregnancy rates. Fertil Steril 1997, 68(6):1004-1010. 10.1016/S0015-0282(97)00392-0, 9418688.
14. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004, 19(9):1993-2000. 10.1093/humrep/deh375, 15284212.
15. Orvieto R, Meltcer S, Homburg R, Nahum R, Rabinson J, Ashkenazi J. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?. Fertil Steril 2009, 91(4 Suppl):1466-1468.
16. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997, 12(11):2359-2365. 10.1093/humrep/12.11.2359, 9436663.
17. Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G, Eestermans W, Gerris J. Characterization of a top quality embryo, a step towards single-embryo transfer. Hum Reprod 1999, 14(9):2345-2349. 10.1093/humrep/14.9.2345, 10469708.
18. Decanter C, Pigny P, Lefebvre C, Thomas P, Leroy M, Dewailly D. Serum inhibin B during controlled ovarian hyperstimulation: an additional criterion for deciding whether to proceed with egg retrieval. Fertil Steril 2009, 91(6):2419-2425. 10.1016/j.fertnstert.2008.03.037, 18555227.
19. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, Dewailly D. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000, 73(5):972-977. 10.1016/S0015-0282(00)00421-0, 10785223.
20. Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008, 90(4):1055-1063. 10.1016/j.fertnstert.2007.07.1354, 18054003.
21. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 2006, 21(2):352-357.
22. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2010, 1:CD006109.
23. Esinler I, Bayar U, Bozdag G, Yarali H. Outcome of intracytoplasmic sperm injection in patients with polycystic ovary syndrome or isolated polycystic ovaries. Fertil Steril 2005, 84(4):932-937. 10.1016/j.fertnstert.2005.04.028, 16213846.
24. Sahu B, Ozturk O, Ranierri M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet 2008, 277(3):239-244. 10.1007/s00404-007-0462-x, 17899140.
25. Swanton A, Storey L, McVeigh E, Child T. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol 2010, 149(1):68-71. 10.1016/j.ejogrb.2009.11.017, 20022685.